Spots Global Cancer Trial Database for multiple myeloma in relapse
Every month we try and update this database with for multiple myeloma in relapse cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma | NCT01329289 | Multiple Myelom... Multiple Myelom... | SOM230 Bortezomib Dexamethasone | 18 Years - | University of Pittsburgh | |
| A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma | NCT05121103 | Multiple Myelom... Diffuse Large B... Diffuse Large B... Multiple Myelom... | EZM0414 | 18 Years - | Ipsen | |
| Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM | NCT05739188 | Multiple Myelom... Multiple Myelom... | Anti-GPRC5D CAR... | 18 Years - 75 Years | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | |
| A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM | NCT04184050 | Multiple Myelom... Multiple Myelom... Multiple Myelom... Multiple Myelom... | HPN217 | 18 Years - | Harpoon Therapeutics | |
| Tinostamustine Conditioning and Autologous Stem Cell | NCT03687125 | Multiple Myelom... Multiple Myelom... Multiple Myelom... | Tinostamustine Autologous Stem... | 18 Years - 75 Years | Mundipharma-EDO GmbH | |
| A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors | NCT06411301 | Multiple Myelom... Multiple Myelom... Multiple Myelom... | 225Ac-DOTATATE | 18 Years - | Jules Bordet Institute | |
| Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse | NCT01794572 | Multiple Myelom... | Melphalan Autologous Hema... | 18 Years - 65 Years | Institut Cancerologie de l'Ouest | |
| Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT03702725 | Refractory Mult... Multiple Myelom... Multiple Myelom... | Ibrutinib Lenalidomide Dexamethasone | 18 Years - | Alliance Foundation Trials, LLC. | |
| a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma | NCT04776330 | Multiple Myelom... Neoplasm, Plasm... Multiple Myelom... | BCMA targeted p... | 18 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma | NCT03030261 | Multiple Myelom... | Elotuzumab Pomalidomide Dexamethasone | 18 Years - 75 Years | Washington University School of Medicine | |
| Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients | NCT02970747 | Multiple Myelom... | Carfilzomib | 18 Years - | iOMEDICO AG | |
| Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients | NCT00401011 | Multiple Myelom... Multiple Myelom... | Perifosine Bortezomib Dexamethasone | 18 Years - | AEterna Zentaris | |
| TriPRIL CAR T Cells in Multiple Myeloma | NCT05020444 | Multiple Myelom... Multiple Myelom... Refractory Mult... | TriPRIL CAR T C... Cyclophosphamid... Fludarabine | 18 Years - | Massachusetts General Hospital | |
| Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines | NCT03155100 | Multiple Myelom... | Carfilzomib for... Elotuzumab 400 ... Dexamethasone | 18 Years - 74 Years | Helsinki University Central Hospital | |
| a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma | NCT04776330 | Multiple Myelom... Neoplasm, Plasm... Multiple Myelom... | BCMA targeted p... | 18 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma | NCT04287855 | Multiple Myelom... Multiple Myelom... | Isatuximab Carfilzomib Pomalidomide Dexamethasone | 18 Years - | Poitiers University Hospital | |
| A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma | NCT03697629 | Multiple Myelom... | Daratumumab | 18 Years - | Canadian Myeloma Research Group | |
| Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma | NCT02666209 | Multiple Myelom... Multiple Myelom... | Ulocuplumab Lenalidomide Bortezomib Dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma | NCT03428373 | Multiple Myelom... Multiple Myelom... Multiple Myelom... Multiple Myelom... Multiple Myelom... Multiple Myelom... | Rivaroxaban ASA | 18 Years - 90 Years | Lawson Health Research Institute | |
| BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma | NCT04162353 | Multiple Myelom... Refractory Mult... Plasmacytoid; L... | BCMA-CD19 cCAR ... | - | iCell Gene Therapeutics | |
| Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma | NCT03767725 | Multiple Myelom... | Treatment | 14 Years - 75 Years | Shenzhen Second People's Hospital | |
| Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM) | NCT01394354 | Multiple Myelom... | Vorinostat Bortezomib Doxorubicin Dexamethasone | 18 Years - | University Hospital Freiburg | |
| Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | NCT01889420 | Multiple Myelom... | Combination the... | 18 Years - | New Mexico Cancer Care Alliance | |
| A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma | NCT01965353 | Multiple Myelom... | Panobinostat Dexamethasone Lenalidomide Bortezomib | 18 Years - | Dana-Farber Cancer Institute | |
| Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma | NCT04063189 | Multiple Myelom... | Clarithromycin ... | 18 Years - | The First Hospital of Jilin University | |
| Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma | NCT02004275 | Multiple Myelom... | pomalidomide ixazomib dexamethasone | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT02176213 | Multiple Myelom... Multiple Myelom... | Pomalidomide Cyclophosphamid... Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma | NCT00410605 | Multiple Myelom... Stage II Multip... Stage III Multi... | bevacizumab lenalidomide dexamethasone | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma | NCT00410605 | Multiple Myelom... Stage II Multip... Stage III Multi... | bevacizumab lenalidomide dexamethasone | 18 Years - | National Cancer Institute (NCI) | |
| Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients | NCT02981199 | Microtransplant... Autologous Stem... Multiple Myelom... | stem cell trans... | 18 Years - 65 Years | Beijing Chao Yang Hospital | |
| Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes | NCT06282978 | Multiple Myelom... | Elranatamab (PF... | 18 Years - | PETHEMA Foundation | |
| A Trial of Selinexor, Ruxolitinib and Methylprednisolone | NCT06225310 | Multiple Myelom... Multiple Myelom... | Selinexor Ruxolitinib Methylprednisol... | - | Oncotherapeutics | |
| Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma | NCT03030261 | Multiple Myelom... | Elotuzumab Pomalidomide Dexamethasone | 18 Years - 75 Years | Washington University School of Medicine | |
| Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies | NCT05191472 | Multiple Myelom... Multiple Myelom... Multiple Myelom... Recurrent Plasm... Refractory Plas... | Pembrolizumab | 18 Years - | University of California, San Francisco | |
| Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma | NCT04063189 | Multiple Myelom... | Clarithromycin ... | 18 Years - | The First Hospital of Jilin University | |
| Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) | NCT01435720 | Multiple Myelom... Multiple Myelom... Mantle Cell Lym... Diffuse Large B... Other B Cell Ly... Plasma Cell Leu... | SNS01-T SNS01-T SNS01-T SNS01-T | 18 Years - | Senesco Technologies, Inc. | |
| TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | NCT03860038 | Multiple Myelom... Refractory Mult... | TJ202 and Dexam... | 18 Years - | TJ Biopharma Co., Ltd. | |
| Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma | NCT04861480 | Multiple Myelom... Multiple Myelom... | C-4-29 Cells | 18 Years - | Chongqing Precision Biotech Co., Ltd | |
| A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory | NCT05581875 | Multiple Myelom... Multiple Myelom... Neoplasms Gammopathy, Mon... Paraproteinemia... Blood Protein D... Haematologic Di... Corneal Disease Neoplasms, Plas... | Belantamab Mafo... Daratumumab Pomalidomide Dexamethasone | 18 Years - | Hellenic Society of Hematology | |
| A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors | NCT06411301 | Multiple Myelom... Multiple Myelom... Multiple Myelom... | 225Ac-DOTATATE | 18 Years - | Jules Bordet Institute | |
| Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma | NCT03428373 | Multiple Myelom... Multiple Myelom... Multiple Myelom... Multiple Myelom... Multiple Myelom... Multiple Myelom... | Rivaroxaban ASA | 18 Years - 90 Years | Lawson Health Research Institute | |
| Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma | NCT02004275 | Multiple Myelom... | pomalidomide ixazomib dexamethasone | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma | NCT01083602 | Relapsed and Bo... Refractory Mult... Multiple Myelom... | panobinostat bortezomib dexamethasone | 18 Years - | Novartis | |
| Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma | NCT03266692 | Multiple Myelom... Multiple Myelom... Refractory Mult... | ACTR087 SEA-BCMA | 18 Years - 80 Years | Cogent Biosciences, Inc. | |
| Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM | NCT05909826 | Multiple Myelom... Multiple Myelom... | Carfilzomib Cyclophosphamid... Dexamethasone | 19 Years - | Dong-A University Hospital | |
| Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | NCT04272151 | Multiple Myelom... Multiple Myelom... Neoplasm, Plasm... | BCMA CAR-T cell... | 18 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | NCT03860038 | Multiple Myelom... Refractory Mult... | TJ202 and Dexam... | 18 Years - | TJ Biopharma Co., Ltd. | |
| A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies | NCT05836896 | Neoplasms Relapsed Diffus... Refractory Diff... Multiple Myelom... Multiple Myelom... | MDC-CAR-BCMA001... | 18 Years - | Technische Universität Dresden | |
| Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse | NCT01794572 | Multiple Myelom... | Melphalan Autologous Hema... | 18 Years - 65 Years | Institut Cancerologie de l'Ouest | |
| TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | NCT03952091 | Multiple Myelom... Refractory Mult... | TJ202, Lenalido... Lenalidomide an... | 18 Years - | TJ Biopharma Co., Ltd. | |
| Tinostamustine Conditioning and Autologous Stem Cell | NCT03687125 | Multiple Myelom... Multiple Myelom... Multiple Myelom... | Tinostamustine Autologous Stem... | 18 Years - 75 Years | Mundipharma-EDO GmbH | |
| Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells | NCT04813653 | Multiple Myelom... Multiple Myelom... | cyclosporine in... | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies | NCT05836896 | Neoplasms Relapsed Diffus... Refractory Diff... Multiple Myelom... Multiple Myelom... | MDC-CAR-BCMA001... | 18 Years - | Technische Universität Dresden | |
| Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs | NCT04985357 | Stage III Breas... Stage IV Breast... Stage III Lung ... Stage IV Lung C... AML Multiple Myelom... Carcinoma Carcinoma, Panc... Carcinoma of Lu... Carcinoma, Non-... Carcinoma Breas... Carcinoma Prost... Carcinoma, Hepa... Carcinoma, Rena... Carcinoma, Neur... Carcinoma, Smal... Carcinoma, Ovar... Carcinoma Bladd... Carcinoma of Es... Carcinoma Cervi... Carcinoma, Thym... Carcinoma, Duct... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of Un... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Malignant Pleur... Malignant Ascit... Mesothelioma Cholangiocarcin... | 18 Years - | Travera Inc | ||
| Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM | NCT06255847 | Multiple Myelom... | Pomalidomide, c... | 18 Years - | Shanxi Bethune Hospital | |
| Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies | NCT05191472 | Multiple Myelom... Multiple Myelom... Multiple Myelom... Recurrent Plasm... Refractory Plas... | Pembrolizumab | 18 Years - | University of California, San Francisco | |
| A Trial of Selinexor, Ruxolitinib and Methylprednisolone | NCT06225310 | Multiple Myelom... Multiple Myelom... | Selinexor Ruxolitinib Methylprednisol... | - | Oncotherapeutics | |
| Long-term KRd in Relapsed and/or Refractory Multiple Myeloma | NCT05495620 | Multiple Myelom... Multiple Myelom... | Carfilzomib Lenalidomide Dexamethasone | 19 Years - | Dong-A University Hospital | |
| Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma | NCT04925193 | Multiple Myelom... | Selinexor Pomalidomide Daratumumab Carfilzomib Dexamethasone | 18 Years - | University of Colorado, Denver | |
| Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib | NCT04790474 | Multiple Myelom... Refractory Mult... | ixazomib-pomali... | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma | NCT03672253 | Multiple Myelom... Multiple Myelom... Multiple Myelom... | CAR-T Re-treatm... | 18 Years - | Second Affiliated Hospital of Xi'an Jiaotong University | |
| A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma | NCT03697629 | Multiple Myelom... | Daratumumab | 18 Years - | Canadian Myeloma Research Group | |
| Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma | NCT05853965 | Multiple Myelom... Multiple Myelom... | Belantamab mafo... | 18 Years - | Universitätsklinikum Hamburg-Eppendorf | |
| Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma | NCT03767725 | Multiple Myelom... | Treatment | 14 Years - 75 Years | Shenzhen Second People's Hospital | |
| Ixazomib + Pomalidomide + Dexamethasone In MM | NCT04094961 | Multiple Myelom... Multiple Myelom... | Ixazomib Pomalidomide Dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma | NCT03136653 | Multiple Myelom... | MP0250 plus BOR... | 18 Years - | Molecular Partners AG | |
| Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma | NCT02103335 | Multiple Myelom... Refractory Mult... Multiple Myelom... | pomalidomide marizomib low-dose dexame... | 18 Years - | Celgene | |
| Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans | NCT03601624 | Multiple Myelom... Multiple Myelom... Refractory Mult... | Pomalidomide | 18 Years - | Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado | |
| TriPRIL CAR T Cells in Multiple Myeloma | NCT05020444 | Multiple Myelom... Multiple Myelom... Refractory Mult... | TriPRIL CAR T C... Cyclophosphamid... Fludarabine | 18 Years - | Massachusetts General Hospital | |
| BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma | NCT04271644 | Multiple Myelom... Neoplasm, Plasm... Multiple Myelom... | BCMA CAR-T cell... | 18 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma | NCT03777410 | Multiple Myelom... | 18 Years - | Travera Inc | ||
| Marizomib Central Nervous System (CNS) | NCT05050305 | Multiple Myelom... Multiple Myelom... Multiple Myelom... | Marizomib Pomalidomide Dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM | NCT04176718 | Multiple Myelom... Refractory Mult... Multiple Myelom... Relapse | Daratumumab Carfilzomib Pomalidomide Dexamethasone | 18 Years - 80 Years | Massachusetts General Hospital | |
| Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse | NCT01794572 | Multiple Myelom... | Melphalan Autologous Hema... | 18 Years - 65 Years | Institut Cancerologie de l'Ouest | |
| Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT03702725 | Refractory Mult... Multiple Myelom... Multiple Myelom... | Ibrutinib Lenalidomide Dexamethasone | 18 Years - | Alliance Foundation Trials, LLC. | |
| A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT03650491 | Multiple Myelom... Multiple Myelom... Multiple Myelom... | FOR46 | 18 Years - | Fortis Therapeutics, Inc. | |
| Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma | NCT03777410 | Multiple Myelom... | 18 Years - | Travera Inc | ||
| Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma | NCT04287855 | Multiple Myelom... Multiple Myelom... | Isatuximab Carfilzomib Pomalidomide Dexamethasone | 18 Years - | Poitiers University Hospital | |
| Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma | NCT05853965 | Multiple Myelom... Multiple Myelom... | Belantamab mafo... | 18 Years - | Universitätsklinikum Hamburg-Eppendorf | |
| SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma | NCT01329289 | Multiple Myelom... Multiple Myelom... | SOM230 Bortezomib Dexamethasone | 18 Years - | University of Pittsburgh |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
